Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed. The drug's high price point has ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Additionally, Praluent was associated with a 15% lower risk of death from any cause, which occurred in 334 (3.5%) of patients in the Praluent group and 392 (4.1%) of patients in the placebo group.

We recently compiled a list of 10 High Growth NASDAQ Stocks That Are Profitable in 2024. In this article, we will look at ...

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 77.14 with a ...

such as Praluent (alirocumab), which reduce LDL levels by binding to a particular protein in the liver Some people with familial hypercholesterolemia (FH), which is genetically inherited, also need to ...

Praluent and Evkeeza have also been impressive sources of sales growth. CFRA has a "buy" rating and $1,185 price target for REGN, which closed at $1,136.35 on Sept. 10. Boston Scientific is a ...

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.

The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology ...

REGN also has smaller franchises like Praluent for cholesterol management and Evkeeza for homozygous familial hypercholesterolemia [HoFH]. While these IPs provide some diversity to REGN’s IP ...

Disruptions from Hurricane Helene exacerbated shortages of critical intravenous fluids in the United States, and now the Biden administration has invoked the wartime powers of the Defense Production ...